Clinical manifestations of children with COVID-19: A systematic review.


Journal

Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590

Informations de publication

Date de publication:
08 2020
Historique:
received: 07 04 2020
accepted: 01 06 2020
pubmed: 4 6 2020
medline: 6 8 2020
entrez: 4 6 2020
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19) outbreak is an unprecedented global public health challenge, leading to thousands of deaths every day worldwide. Despite the epidemiological importance, clinical patterns of children with COVID-19 remain unclear. The aim of this study was to describe the clinical, laboratorial, and radiological characteristics of children with COVID-19. The Medline database was searched between December 1st 2019 and April 6th 2020. No language restrictions were applied. Inclusion criteria were (a) studied patients younger than 18 years old; (b) presented original data from cases of COVID-19 confirmed by reverse-transcription polymerase chain reaction; and (c) contained descriptions of clinical manifestations, laboratory tests, or radiological examinations. A total of 38 studies (1124 cases) were included. From all the cases, 1117 had their severity classified: 14.2% were asymptomatic, 36.3% were mild, 46.0% were moderate, 2.1% were severe, and 1.2% were critical. The most prevalent symptom was fever (47.5%), followed by cough (41.5%), nasal symptoms (11.2%), diarrhea (8.1%), and nausea/vomiting (7.1%). One hundred forty-five (36.9%) children were diagnosed with pneumonia and 43 (10.9%) upper airway infections were reported. Reduced lymphocyte count was reported in 12.9% of cases. Abnormalities in computed tomography were reported in 63.0% of cases. The most prevalent abnormalities reported were ground-glass opacities, patchy shadows, and consolidations. Only one death was reported. Clinical manifestations of children with COVID-19 differ widely from adult cases. Fever and respiratory symptoms should not be considered a hallmark of COVID-19 in children.

Sections du résumé

BACKGROUND
The coronavirus disease 2019 (COVID-19) outbreak is an unprecedented global public health challenge, leading to thousands of deaths every day worldwide. Despite the epidemiological importance, clinical patterns of children with COVID-19 remain unclear. The aim of this study was to describe the clinical, laboratorial, and radiological characteristics of children with COVID-19.
METHODS
The Medline database was searched between December 1st 2019 and April 6th 2020. No language restrictions were applied. Inclusion criteria were (a) studied patients younger than 18 years old; (b) presented original data from cases of COVID-19 confirmed by reverse-transcription polymerase chain reaction; and (c) contained descriptions of clinical manifestations, laboratory tests, or radiological examinations.
RESULTS
A total of 38 studies (1124 cases) were included. From all the cases, 1117 had their severity classified: 14.2% were asymptomatic, 36.3% were mild, 46.0% were moderate, 2.1% were severe, and 1.2% were critical. The most prevalent symptom was fever (47.5%), followed by cough (41.5%), nasal symptoms (11.2%), diarrhea (8.1%), and nausea/vomiting (7.1%). One hundred forty-five (36.9%) children were diagnosed with pneumonia and 43 (10.9%) upper airway infections were reported. Reduced lymphocyte count was reported in 12.9% of cases. Abnormalities in computed tomography were reported in 63.0% of cases. The most prevalent abnormalities reported were ground-glass opacities, patchy shadows, and consolidations. Only one death was reported.
CONCLUSIONS
Clinical manifestations of children with COVID-19 differ widely from adult cases. Fever and respiratory symptoms should not be considered a hallmark of COVID-19 in children.

Identifiants

pubmed: 32492251
doi: 10.1002/ppul.24885
pmc: PMC7300659
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1892-1899

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Curr Med Sci. 2020 Apr;40(2):275-280
pubmed: 32207032
Lancet Child Adolesc Health. 2020 May;4(5):405-406
pubmed: 32213326
World J Pediatr. 2020 Jun;16(3):251-259
pubmed: 32193831
Pediatr Pulmonol. 2020 May;55(5):1169-1174
pubmed: 32134205
Sci China Life Sci. 2020 May;63(5):706-711
pubmed: 32146694
Pediatr Pulmonol. 2020 Aug;55(8):1892-1899
pubmed: 32492251
J Infect Dis. 2020 May 11;221(11):1775-1781
pubmed: 32179908
J Paediatr Child Health. 2020 Apr;56(4):650-651
pubmed: 32202014
J Korean Med Sci. 2020 Mar 23;35(11):e124
pubmed: 32193905
Zhonghua Er Ke Za Zhi. 2020 Apr 2;58(4):269-274
pubmed: 32118389
World J Pediatr. 2020 Jun;16(3):267-270
pubmed: 32180140
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Pediatr Pulmonol. 2020 Jun;55(6):E6-E9
pubmed: 32243729
Zhonghua Er Ke Za Zhi. 2020 Feb 11;58(0):E006
pubmed: 32043842
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Emerg Infect Dis. 2020 Jun;26(6):1337-1339
pubmed: 32150527
Lancet Infect Dis. 2020 May;20(5):559-564
pubmed: 32220284
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Infect Dis. 2020 Sep 12;71(6):1547-1551
pubmed: 32112072
N Engl J Med. 2020 Apr 2;382(14):1370-1371
pubmed: 32163697
Pediatr Pulmonol. 2020 Jun;55(6):E4-E5
pubmed: 32250049
Zhonghua Er Ke Za Zhi. 2020 Feb 04;58(0):E002
pubmed: 32023679
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Infect Dis (Lond). 2020 Jun;52(6):427-429
pubmed: 32233816
Emerg Microbes Infect. 2020 Dec;9(1):707-713
pubmed: 32208917
Zhongguo Dang Dai Er Ke Za Zhi. 2020 Mar;22(3):211-214
pubmed: 32204755
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
J Infect Dis. 2020 May 11;221(11):1770-1774
pubmed: 32179910
JAMA. 2020 May 26;323(20):2085-2086
pubmed: 32293646
J Infect. 2020 May;80(5):e7-e13
pubmed: 32171865
Lancet Infect Dis. 2020 Jun;20(6):689-696
pubmed: 32220650
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Zhonghua Er Ke Za Zhi. 2020 Feb 16;58(0):E007
pubmed: 32061200
Zhonghua Er Ke Za Zhi. 2020 Feb 09;58(0):E004
pubmed: 32035429
Zhonghua Er Ke Za Zhi. 2020 Feb 11;58(0):E005
pubmed: 32045966
JAMA Pediatr. 2020 Jul 1;174(7):722-725
pubmed: 32215598
Zhonghua Er Ke Za Zhi. 2020 Feb 17;58(0):E009
pubmed: 32065520
Zhongguo Dang Dai Er Ke Za Zhi. 2020 Mar;22(3):221-225
pubmed: 32204757
J Med Virol. 2020 Jul;92(7):909-914
pubmed: 32222992
J Comput Assist Tomogr. 2020 May/Jun;44(3):311-313
pubmed: 32217900
JAMA Pediatr. 2020 Sep 01;174(9):868-873
pubmed: 32392288
Pediatr Pulmonol. 2020 May;55(5):E1-E4
pubmed: 32187887
JAMA. 2020 Apr 7;323(13):1313-1314
pubmed: 32058570
Lancet Infect Dis. 2020 Apr;20(4):410-411
pubmed: 32087116
Clin Infect Dis. 2020 Jul 28;71(15):847-849
pubmed: 32112082
Zhongguo Dang Dai Er Ke Za Zhi. 2020 Mar;22(3):215-220
pubmed: 32204756
Nat Med. 2020 Apr;26(4):502-505
pubmed: 32284613

Auteurs

Tiago H de Souza (TH)

Pediatric Intensive Care Unit, Department of Pediatrics, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.

José A Nadal (JA)

Pediatric Intensive Care Unit, Department of Pediatrics, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.

Roberto J N Nogueira (RJN)

Pediatric Intensive Care Unit, Department of Pediatrics, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Department of Pediatrics, School of Medicine São Leopoldo Mandic, Campinas, São Paulo, Brazil.

Ricardo M Pereira (RM)

Pediatric Intensive Care Unit, Department of Pediatrics, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.

Marcelo B Brandão (MB)

Pediatric Intensive Care Unit, Department of Pediatrics, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH